A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

CONCLUSION: Sunitinib demonstrated minimal activity in the second- and third-line treatment of persistent or recurrent clear cell ovarian carcinoma. ClinicalTrials.gov number, NCT00979992. PMID: 29921512 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29921512?dopt=Abstract

Source: Gynecologic Oncology - June 16, 2018 Category: Cancer & Oncology Authors: Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM Tags: Gynecol Oncol Source Type: research